Novartis to Pay $2B for Synnovation Breast Cancer Drug
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Novartis announced it will acquire Synnovation Therapeutics’ experimental breast‑cancer drug SNV4818 for a $2 billion upfront payment.
- Synnovation will receive up to $1 billion in additional milestone payments if the drug meets specified development targets.
- SNV4818 is currently in a Phase 1/2 clinical trial for HR‑positive, HER2‑negative breast cancer.
- SNV4818 is designed to inhibit a mutated form of the PI3Kα enzyme while sparing the normal protein in healthy cells.
- Novartis disclosed the transaction on Friday, adding a targeted oral therapy to its oncology pipeline.
Why it matters: Novartis secures a promising targeted therapy that expands its breast‑cancer pipeline, while Synnovation receives a $2 billion upfront cash infusion and up to $1 billion in milestone upside, shifting development risk to the larger partner. The drug’s design to hit mutated PI3Kα while sparing normal cells underscores its differentiated approach.
Ask SkimNews
